The NeuroEndocrine Cancer Australia (NECA) NET nurse service often guides patients through the PRRT procedure as part of their Telehealth support service. And now NECA created and launched a new explainer video that can be viewed on demand. And the demand has been high, with over 500 patients viewing the video in the first month.
Peptide receptor radionuclide therapy (PRRT) or Lutate PRRT is an outpatient therapy that is effective for some patients with neuroendocrine tumors (NETs). Lutetium-177 octreotate therapy (Lutate) is primarily used to treat people with NETs in Australia when other types of treatment, such as surgery or chemotherapy, are not suitable or are ineffective. This may be due to the size, location and number of tumors present. Lutetium-177 octreotate is a very specific therapy that can only be used when tumors express a large number of somatostatin receptors. Many NETs show an increase in somatostatin receptors. If this therapy is being considered, a diagnostic scan is performed (Gallium 68 PET/CT scan) to distinguish if the tumors are positive for somatostatin receptors.
